Clinical Trials Logo

Healthy clinical trials

View clinical trials related to Healthy.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT03921333 Not yet recruiting - Healthy Clinical Trials

The Effect of a Botanical Plant Extract on Gut Health, Immunity and Metabolic Disorders in Healthy Adults

GHIMD
Start date: July 2019
Phase: N/A
Study type: Interventional

There is an enormous increase in diabetes mellitus worldwide, especially in developed countries. Ninety percent of diabetes cases worldwide are of Type II diabetes mellitus (T2DM) as a result of greater prevalence of sedentary lifestyle, unhealthy diet and rise of obesity, as well as an increasing number of elderly populations. T2DM can be attributed to relative deficiency of insulin involving insulin resistance, aberrant synthesis of hepatic glucose and progressive deterioration of pancreatic beta-cell functions resulting in chronic hyperglycaemia. A growing amount of evidence has emerged in the last several years linking various nutrients and food sources with a positive management of T2DM. In in vitro studies, various botanical extracts have been found to significantly inhibit the activity of alpha-glucosidase and alpha-amylase. The inhibition of these enzymes' activity is a rational approach in managing glucose level for borderline and T2DM sufferers as inhibition of both alpha-amylase and alpha-glucosidase activity can profoundly reduce post-prandial increase in blood plasma glucose concentration following a mixed carbohydrate intake. Excessive levels of blood plasma glucose and free fatty acids impose a stressful condition for pancreatic beta-cells and other insulin sensitive cells resulting in the local secretion of pro-inflammatory cytokines and chemokines causing a continuous low levels of abnormal inflammation that alter insulin's action. As the body becomes less sensitive to insulin, the resulting insulin resistance leads to further inflammation, with more inflammation causing more insulin resistance, causing blood plasma sugar levels to continuously increase, eventually resulting in T2DM. In in vitro animal models, various compounds of botanical origin have also been shown to possess anti-inflammatory activities which can be beneficial in managing T2DM.

NCT ID: NCT03917628 Not yet recruiting - Healthy Clinical Trials

Pharmacokinetics and Safety in Healthy Volunteers

Start date: May 15, 2019
Phase: Phase 1
Study type: Interventional

Investigate the pharmacokinetics, safety and tolerability of SCT630 and to establish pharmacokinetic similarity of SCT630 to adalimumab.

NCT ID: NCT03915886 Not yet recruiting - Healthy Clinical Trials

A Study of JNJ-64530440 in Healthy Japanese Male Participants

Start date: April 12, 2019
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety, tolerability, and pharmacokinetics (PK) of JNJ-64530440 (JNJ-0440) in healthy Japanese adult male participants after single oral dose administration with ascending dose design.

NCT ID: NCT03914755 Not yet recruiting - Healthy Clinical Trials

A Safety, Tolerability, and Pharmacokinetic Study of Tucatinib in Healthy Japanese and Caucasian Subjects

Start date: April 2019
Phase: Phase 1
Study type: Interventional

This study is being done to compare the pharmacokinetics (PK) and safety/tolerability of tucatinib in healthy Japanese and Caucasian participants. Three cohorts of healthy Japanese and Caucasian men and women will be admitted to the Clinical Research Unit (CRU) and receive multiple oral doses of tucatinib over 14 days with and without food. Subjects will be in the study for up to 45 days, including the screening period. Due to practical considerations, each cohort will be dosed sequentially (this is not a dose escalation study).

NCT ID: NCT03913260 Not yet recruiting - Healthy Clinical Trials

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

The main purposes of this study are: 1. To learn more about the safety and side effects of different formulations of LY3375880 and 2. To measure how much LY3375880 gets into the blood stream and how long it takes to get out of the body. The study will last about 85 days. Screening may occur up to 28 days prior to enrollment.

NCT ID: NCT03912974 Not yet recruiting - Healthy Clinical Trials

Effects of SERT Inhibition on the Subjective Response to Psilocybin in Healthy Subjects

Start date: May 1, 2019
Phase: Phase 1
Study type: Interventional

Psilocybin is a classic serotonergic hallucinogen acting on the 5-HT2A receptor. It is used recreationally and in psychiatric research. Selective serotonin reuptake inhibitors (SSRIs) like escitalopram are first-line treatments for depression. They inhibit the serotonin transporter (SERT). This might cause a possible downregulation of postsynaptic 5-HT receptors, e.g. the 5-HT2A receptor. The aim of the study is to investigate the effects of psilocybin after escitalopram and Placebo pretreatment. Subjective and physiological effects as well as effects on gene expression will be assessed.

NCT ID: NCT03907280 Not yet recruiting - Healthy Clinical Trials

A Study in Healthy Men That Tests if Taking BI 1265162 by Mouth, Intravenously, or Inhaled Influences the Amount of BI 1265162 in the Blood

Start date: April 23, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to investigate the absolute bioavailability of BI 1265162 following administration of oral solution and inhaled via Respimat.

NCT ID: NCT03904576 Not yet recruiting - Healthy Clinical Trials

A Study in Healthy Men to Test Whether BI 1358894 Reduces Druginduced Panic Symptoms

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

The main objective of this trial is to investigate the pharmacodynamic effects of a single dose of BI 1358894 on CCK-4- induced anxiogenic/ panic-like symptoms using the PSS in preselected CCK-4 sensitive healthy volunteers.

NCT ID: NCT03902106 Not yet recruiting - Healthy Clinical Trials

Physiological Response to Salbutamol and Exercise

Start date: April 15, 2019
Phase: N/A
Study type: Interventional

The scope of the study is to investigate the physiological response to salbutamol and exercise. A particular focus is on the metabolic response and amine metabolism.

NCT ID: NCT03901508 Not yet recruiting - Healthy Clinical Trials

A Single Session of tDCS (Transcranial Direct Current Stimulation) Improves Endurance for 30 Minutes

Start date: April 5, 2019
Phase: N/A
Study type: Interventional

Healthy recreational athletes will undergo a session of anodal tDCS (transcranial direct current stimulation) or sham tDCS. The primary outcome is an isokinetic evaluation of their hamstrings' and quadriceps' strength before and after each session